The global BCG tuberculosis (TB) vaccine market is expected to grow at a significant during the forecast period (2021-2027). The bacteria Mycobacterium tuberculosis causes tuberculosis. TB damages the lungs and spreads through the air from person to person. Tuberculosis is preventive and curable, and therapy includes the administration of the Bacille Calmette-Guérin (BCG) vaccine. The BCG Tuberculosis (TB) Vaccine is made with a weakened TB bacterium strain. Although there is presently no effective vaccination to prevent tuberculosis in adults, the BCG TB vaccine is routinely used to protect children against severe forms of illness.

According to WHO, Tuberculosis (TB) was one of the top 10 causes of death in 2018, killing 1.5 million people. The bulk of cases were recorded in Southeast Asia, driving up demand for the BCG TB vaccination. According to NCBI, it has been shown that HIV patients are 19 times more likely to contract TB, therefore the growing number of HIV globally is expected to drive the market growth of global BCG TB Vaccines during the forecast period.

The market is expected to develop due to rising vaccination awareness, increased government financing for vaccination programmes, and an increase in the prevalence of infectious diseases. The market's growth is also driven by improved healthcare infrastructure and a focus on illness prevention. The sector has a problem due to demand inflexibility. Middle-income nations are also experiencing supply issues, whereas high-income countries have had no more challenges beyond the first pressure. For instance, At Maldives's request, India immediately delivered a supply of 2400 vials of BCG vaccine in 2020 to fill a gap in the Maldives' National Immunization Program. Therefore, the supply-demand gap in developing countries is expected to drive the market for global BCG TB vaccines during the forecast period.

The rising R&D initiatives in the health care sector is also expected to drive the market for the BCG TB vaccine. In 2019, the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) began an initiative to better understand the immune response required to defend against M. tuberculosis infection.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Drug Type 

o By End-User

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Sanofi, Serum Institute of India Pvt. Ltd., InterVax Ltd, Merck & Co. Inc., China National Pharmaceutical Group Corporation. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global BCG Tuberculosis (TB) Vaccine Market by Segments

By Drug Type

• Immune BCG
• Therapy BCG

By End-User

• Paediatrics
• Adults

Global BCG Tuberculosis (TB) Vaccine Market by Region